Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Acute lymphoblastic leukaemia
Author: Inaba, H.
Greaves, M.
Mullighan, C.G.
Citation: Lancet, 2013; 381(9881):1943-1955
Publisher: Elsevier
Issue Date: 2013
ISSN: 0140-6736
Statement of
Hiroto Inaba, Mel Greaves, Charles G Mullighan
Abstract: Acute lymphoblastic leukaemia occurs in both children and adults but its incidence peaks between 2 and 5 years of age. Causation is multifactorial and exogenous or endogenous exposures, genetic susceptibility, and chance have roles. Survival in paediatric acute lymphoblastic leukaemia has improved to roughly 90% in trials with risk stratification by biological features of leukaemic cells and response to treatment, treatment modification based on patients' pharmacodynamics and pharmacogenomics, and improved supportive care. However, innovative approaches are needed to further improve survival while reducing adverse effects. Prognosis remains poor in infants and adults. Genome-wide profiling of germline and leukaemic cell DNA has identified novel submicroscopic structural genetic changes and sequence mutations that contribute to leukaemogenesis, define new disease subtypes, affect responsiveness to treatment, and might provide novel prognostic markers and therapeutic targets for personalised medicine.
Keywords: Central Nervous System Diseases
Rights: © 2013 Elsevier Ltd. All rights reserved.
RMID: 0030061219
DOI: 10.1016/S0140-6736(12)62187-4
Appears in Collections:Genetics publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.